Skip to main content
VCbacked
Log inGet Started

Aditxt Therapeutics

Loma Linda, United States

Aditxt Therapeutics is a biotechnology company that develops a novel nucleic acid-based technology.

$1.2M raised
Aug 2024
Post-IPO Equity
BiotechnologyHealth CareTherapeutics

Top Investors

U.S. Department of War

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Aditxt Therapeutics

How much funding has Aditxt Therapeutics raised?
Aditxt Therapeutics has raised $1.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in August 2024.
Who are Aditxt Therapeutics's investors?
Aditxt Therapeutics's investors include U.S. Department of War.
Where is Aditxt Therapeutics headquartered?
Aditxt Therapeutics is headquartered in Loma Linda, United States.
What does Aditxt Therapeutics do?
Aditxt Therapeutics is a biotechnology company that develops a novel nucleic acid-based technology.
What stage is Aditxt Therapeutics at?
Aditxt Therapeutics is at the Post-IPO Equity stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Aditxt Therapeutics — Funding & Investors." VCBacked, August 9, 2024, https://www.vcbacked.co/company/aditxt-therapeutics. Accessed July 3, 2026.
APA
VCBacked. (2024). Aditxt Therapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/aditxt-therapeutics
Wikipedia (cite web)
{{cite web |title=Aditxt Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aditxt-therapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Rapport Therapeutics
Boston$250.0M
Allterum Therapeutics
Houston$1.0M
AlpalifeBio
Woburn$9.8M
Renaissance BioScience
Vancouver$599K
Epsilogen
London$16.3M
Advanced Microbiome Interventions
Amsterdam$300K